InvestorsHub Logo
Followers 43
Posts 899
Boards Moderated 0
Alias Born 05/12/2001

Re: db7 post# 20

Thursday, 12/05/2019 7:52:20 PM

Thursday, December 05, 2019 7:52:20 PM

Post# of 110
Lake Street Capital Markets Analyst Thomas Flaten initiated coverage of DermTech, Inc. with a BUY rating and price target of $15 (DMTK $7.60).

DermTech is a molecular diagnostics company developing and marketing novel gene expression-based tests for various dermatologic applications, including the Pigmented Lesion Assay for the diagnosis of melanoma. Combining gene expression assays with the Company’s adhesive patch technology allows for non-invasive testing. In addition to advancing a proprietary pipeline of diagnostic tests, the Company also partners with pharmaceutical companies for the use of its core technology in clinical studies.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DMTK News